Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma

被引:105
作者
Bergsagel, PL
Kuehl, WM
机构
[1] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[2] NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1034/j.1600-065X.2003.00052.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple myeloma (MM) is a tumor of long-lived bone marrow plasma cells (PCs). Nearly 40% of MM tumors have immunoglobulin H (IgH) translocations involving four recurrent chromosomal loci (oncogenes): 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (MMSET and FGFR3), and 16q23 (c-maf). Other MM tumors have Ig translocations involving different loci, none of which is involved in more than 1% of tumors. At least 25% of MM tumors have no Ig translocation. Unlike normal PCs, MM tumors usually express one of the three cyclin D genes at a high level. Translocations involving 4p16 and 16q23 do not directly target a cyclin D gene, but they are associated with a high level of cyclin D2 expression. Although cyclin D1 is not expressed in normal hematopoietic cells, one-third of MM tumors ectopically express cyclin D1 in the absence of t(11;14). Despite a low proliferation index in MM, dysregulation of a cyclin D gene seems to be a unifying oncogenic event. Analysis of 34 MM cell lines indicates that tumors having an IgH translocation are significantly over-represented, whereas tumors that ectopically express cyclin D1 are not represented. We speculate that ectopic cyclin D1 expression without t(11;14) is dependent on tumor-specific interaction with bone marrow stromal cells.
引用
收藏
页码:96 / 104
页数:9
相关论文
共 30 条
[21]   Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma [J].
Rajkumar, SV ;
Fonseca, R ;
Dewald, GW ;
Therneau, TM ;
Lacy, MQ ;
Kyle, RA ;
Greipp, PR ;
Gertz, MA .
CANCER GENETICS AND CYTOGENETICS, 1999, 113 (01) :73-77
[22]  
Ries L.A., 2002, SEER CANC STAT REV 1
[23]  
SANTRA M, 2002, BLOOD
[24]   Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping [J].
Sawyer, JR ;
Lukacs, JL ;
Munshi, N ;
Desikan, KR ;
Singhal, S ;
Mehta, J ;
Siegel, D ;
Shaughnessy, J ;
Barlogie, B .
BLOOD, 1998, 92 (11) :4269-4278
[25]   Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma [J].
Sawyer, JR ;
Lukacs, JL ;
Thomas, EL ;
Swanson, CM ;
Goosen, LS ;
Sammartino, G ;
Gilliland, JC ;
Munshi, NC ;
Tricot, G ;
Shaughnessy, JD ;
Barlogie, B .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) :167-174
[26]   Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma [J].
Shaughnessy, J ;
Gabrea, A ;
Qi, Y ;
Brents, L ;
Zhan, FH ;
Tian, EM ;
Sawyer, J ;
Barlogie, B ;
Bergsagel, PL ;
Kuehl, M .
BLOOD, 2001, 98 (01) :217-223
[27]   The RB and p53 pathways in cancer [J].
Sherr, CJ ;
McCormick, F .
CANCER CELL, 2002, 2 (02) :103-112
[28]   Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma [J].
Shou, YP ;
Martelli, ML ;
Gabrea, A ;
Qi, Y ;
Brents, LA ;
Roschke, A ;
Dewald, G ;
Kirsch, IR ;
Bergsagel, PL ;
Kuehl, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (01) :228-233
[29]   Generation of polyclonal plasmablasts from peripheral blood B cells:: a normal counterpart of malignant plasmablasts [J].
Tarte, K ;
De Vos, J ;
Thykjaer, T ;
Zhan, FH ;
Fiol, G ;
Costes, V ;
Rème, T ;
Legouffe, E ;
Rossi, JF ;
Shaughnessy, J ;
Orntoft, TF ;
Klein, B .
BLOOD, 2002, 100 (04) :1113-1122
[30]   Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells [J].
Zhan, FH ;
Hardin, J ;
Kordsmeier, B ;
Bumm, K ;
Zheng, MZ ;
Tian, EM ;
Sanderson, R ;
Yang, Y ;
Wilson, C ;
Zangari, M ;
Anaissie, E ;
Morris, C ;
Muwalla, F ;
van Rhee, F ;
Fassas, A ;
Crowley, J ;
Tricot, G ;
Barlogie, B ;
Shaughnessy, J .
BLOOD, 2002, 99 (05) :1745-1757